perioperative – Talk Bio

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

7 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

7 months ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial

FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC

9 months ago talkbio0Tagged AdComm, AstraZeneca, Imfinzi, Immune Checkpoint Inhibitors, Immunologic Adjuvants, Neoadjuvant Chemotherapy, Non-Small Cell Lung Carcinoma, Overtreatment, perioperative, Single Agent Therapy, United States Food and Drug Administration

AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy

FDA Advisers Call for Revamp of Perioperative Lung Cancer Trials Due to Frustration with AstraZeneca’s Imfinzi Design

9 months ago talkbio0Tagged AstraZeneca, Imfinzi, issues, Malignant neoplasm of lung, perioperative, United States Food and Drug Administration

FDA, Imfinzi, AstraZeneca, perioperative lung cancer trials, revamp, design issues